Current research advance on cellular immunotherapy for leukemia-review / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 1326-1330, 2013.
Article
in Chinese
| WPRIM
| ID: wpr-265020
ABSTRACT
Despite the chemotherapy is successful in inducing remission of hematologic malignancy, this disease also has a high probability of relapse; besides, the toxicity of chemotherapy for these patients can not be avoided. Researchers have been attempting to eliminate tumor cells by immunotherapy. Recently, various leukemia-associated antigens (LAA) that are recognized by cytotoxic T cell (CTL) in the context of HLA class I molecules have been identified. These LAA include WT1, PR-3, RHAMM, BCR-ABL and Aur-A. On the basis of these findings, various clinical trials of immunotherapy for hematologic malignancy including tumor peptide vaccination, adoptive T cell therapy, NK cell therapy and dendritic cells-cytokine induced killer (DC-CIK) cell therapy are on going. In this review, the current status and future feasibility of cellular immunotherapy for leukemia are discussed.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Therapeutics
/
T-Lymphocytes, Cytotoxic
/
Leukemia
/
Immunotherapy, Adoptive
/
Allergy and Immunology
Type of study:
Prognostic study
Limits:
Humans
Language:
Chinese
Journal:
Journal of Experimental Hematology
Year:
2013
Type:
Article
Similar
MEDLINE
...
LILACS
LIS